HB-EGF is a potent inducer of tumor growth and angiogenesis

Cancer Research

Volumn 64, Issue 15, 2004, Pages 5283-5290

  Ongusaha, Pat P ^a   Kwak, Jennifer C ^a   Zwible, Andrew J ^a   Macip, Salvador ^b   Higashiyama, Shigeki ^c   Taniguchi, Naoyuki ^d   Fang, Li ^e   Lee, Sam W ^a,f  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^e Telik Inc   (United States)

^f HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CYCLIN D1; GELATINASE B; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; METALLOPROTEINASE; STROMELYSIN; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; AUTOCRINE EFFECT; BLADDER CANCER; CELL GROWTH; CELL SURFACE; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG POTENCY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PARACRINE SIGNALING; PHENOTYPE; PRIORITY JOURNAL; TUMOR GROWTH; WILD TYPE;

ANIMALS; BLOTTING, NORTHERN; CELL DIVISION; CELL MEMBRANE; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; COLONY-FORMING UNITS ASSAY; CYCLIN D1; CYTOSOL; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION REGULATION; HUMANS; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PHENOTYPE; PROMOTER REGIONS (GENETICS); TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

EID: 3442893262     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0925     Document Type: Article

References (50)

1. Raab G, Klagsbrun M. Heparin-binding EGF-like growth factor. Biochim Biophys Acta 1997;1333:F179-99.
2. Higashiyama S, Abraham JA, Miller J, Fiddes JC, Klagsbrun MA. Heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science (Wash. DC) 1991;251:936-9.
3. Blotnick S, Peoples GE, Freeman MR, Eberlein TJ, Klagsbrun MT. Lymphocytes synthesize and export heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor, mitogens for vascular cells and fibroblasts: differential production and release by CD4+ and CD8+ T cells. Proc Natl Acad Sci USA 1994;91:2890-4.
4. Fukuda K, Inui Y, Kawata S, et al. Increased mitogenic response to heparin-binding epidermal growth factor-like growth factor in vascular smooth muscle cells of diabetic rats. Arterioscler Thromb Vasc Biol 1995;15:1680-7.
5. Dluz SM, Higashiyama S, Damm D, Abraham JA, Klagsbrun M. Heparin-binding epidermal growth factor-like growth factor expression in cultured fetal human vascular smooth muscle cells. Induction of mRNA levels and secretion of active mitogen. J Biol Chem 1993;268:18330-4.
6. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997;16:1647-55.
7. Iwamoto R, Mekada E. Heparin-binding EGF-like growth factor: ajuxtacrine growth factor. Cytokine Growth Factor Rev 2000;11:335-44.
8. Hisaka T, Yano H, Haramaki M, Utsunomiya I, Kojiro M. Expressions of epidermal growth factor family and its receptor in hepatocellular carcinoma cell lines: relationship to cell proliferation. Int J Oncol 1999;14:453-60.
9. Murayama Y, Miyagawa J, Shinomura Y, et al. Significance of the association between heparin-binding epidermal growth factor-like growth factor and CD9 in human gastric cancer. Int J Cancer 2002;98:505-13.
10. 1 in normal human tissues. J Histochem Cytochem 2001;49:439-44.
11. Hashimoto K, Higashiyama S, Asada H, et al. Heparin-binding epidermal growth factor-like growth factor is an autocrine growth factor for human keratinocytes. J Biol Chem 1994;269:20060-6.
12. Nishi E, Prat A, Hospital V, Elenius K, Klagsbrun M. N-Arginine dibasic convertase is a specific receptor for heparin-binding EGF-like growth factor that mediates cell migration. EMBO J 2001;20:3342-50.
13. Suo Z, Risberg B, Karlsson MG, Villman K, Skovlund E, Nesland JM. The expression of EGFR family ligands in breast carcinomas. Int J Surg Pathol 2002;10:91-9.
14. Tarbe N, Losch S, Burtscher H, Jarsch M, Weidle UH. Identification of rat pancreatic carcinoma genes associated with lymphogenous metastasis. Anticancer Res 2002;22:2015-27.
15. Fu S, Bottoli I, Goller M, Vogt PK. Heparin-binding epidermal growth factor-like growth factor, a v-Jun target gene, induces oncogenic transformation. Proc Natl Acad Sci USA 1999;96:5716-21.
16. McCarthy SA, Chen D, Yang BS, et al. Rapid phosphorylation of Ets-2 accompanies mitogen-activated protein kinase activation and the induction of heparin-binding epidermal growth factor gene expression by oncogenic Raf-1. Mol Cell Biol 1997;17:2401-12.
17. Martinez-Lacaci I, De Santis M, Kannan S, et al. Regulation of heparin-binding EGF-like growth factor expression in Ha-ras transformed human mammary epithelial cells. J Cell Physiol 2001;186:233-42.
18. Fang L, Li G, Liu G, Lee SW, Aaronson SA. p53 induction of heparin-binding EGF-like growth factor counteracts p53 growth suppression through activation of MAPK and PI3K/Akt signaling cascades. EMBO J 2001;20:1931-9.
19. Miyoshi E, Higashiyama S, Nakagawa T, Hayashi N, Taniguchi N. Membrane-anchored heparin-binding epidermal growth factor-like growth factor acts as a tumor survival factor in a hepatoma cell line. J Biol Chem 1997;272:14349-55.
20. Downing MT, Brigstock DR, Luquette MH, Crissman-Combs M, Besner GE. Immunohistochemical localization of heparin-binding epidermal growth factor-like growth factor in normal skin and skin cancers. Histochem J 1997;29:735-44.
21. Fishman S, Brill S, Papa M, Halpern Z, Zvibel I. Heparin-derived disaccharides modulate proliferation and Erb-B2-mediated signal transduction in colon cancer cell lines. Int J Cancer 2002;99:179-84.
22. Ito Y, Takeda T, Higashiyama S, Noguchi S, Matsuura N. Expression of heparin-binding epidermal growth factor-like growth factor in breast carcinoma. Breast Cancer Res Treat 2001;67:81-5.
23. Ito Y, Takeda T, Higashiyama S, et al. Expression of heparin binding epidermal growth factor-like growth factor in hepatocellular carcinoma: an immunohistochemical study. Oncol Rep 2001;8:903-7.
24. Jayne DG, Perry SL, Morrison E, Farmery SM, Guillou PJ. Activated mesothelial cells produce heparin-binding growth factors: implications for tumour metastases. Br J Cancer 2000;82:1233-8.
25. Kim J, Adam RM, Freeman MR. Activation of the Erk mitogen-activated protein kinase pathway stimulates neuroendocrine differentiation in LNCaP cells independently of cell cycle withdrawal and STATS phosphorylation. Cancer Res 2002;62:1549-54.
26. Thogersen VB, Sorensen BS, Poulsen SS, Orntoft TF, Wolf H, Nexo E. A subclass of HER1 ligands are prognostic markers for survival in bladder cancer patients. Cancer Res 2001;61:6227-33.
27. Wang YD, De Vos J, Jourdan M, et al. Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells. Oncogene 2002;21:2584-92.
28. Kobrin MS, Funatomi H, Friess H, Buchler MW, Stathis P, Korc M. Induction and expression of heparin-binding EGF-like growth factor in human pancreatic cancer. Biochem Biophys Res Commun 1994;202:1705-9.
29. Ito N, Kawata S, Tamura S, et al. Heparin-binding EGF-like growth factor is a potent mitogen for rat hepatocytes. Biochem Biophys Res Commun 1994;198:25-31.
30. Sato M, Narita T, Kawakami-Kimura N, et al. Increased expression of integrins by heparin-binding EGF like growth factor in human esophageal cancer cells. Cancer Lett 1996;102:183-91.
31. Ruck A, Paulie S. EGF, TGF alpha, AR and HB-EGF are autocrine growth factors for human bladder carcinoma cell lines. Anticancer Res 1998;18:1447-52.
32. Murayama Y, Miyagawa J, Higashiyama S, et al. Localization of heparin-binding epidermal growth factor-like growth factor in human gastric mucosa. Gastroenterology 1995;109:1051-9.
33. Higashiyama S, Lau K, Besner GE, Abraham JA, Klagsbrun M. Structure of heparin-binding EGF-like growth factor. Multiple forms, primary structure, and glycosylation of the mature protein. J Biol Chem 1992;267:6205-12.
34. McCarthy SA, Samuels ML, Pritchard CA, Abraham JA, McMahon M. Rapid induction of heparin-binding epidermal growth factor/diphtheria toxin receptor expression by Raf and Ras oncogenes. Genes Dev 1995;9:1953-64.
35. Wulf GM, Ryo A, Wulf GG, et al. Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J 2001;20:3459-72.
36. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
37. Abramovitch R, Neeman M, Reich R, et al. Intercellular communication between vascular smooth muscle and endothelial cells mediated by heparin-binding epidermal growth factor-like growth factor and vascular endothelial growth factor. FEBS Lett 1998;425:441-7.
38. Abramovitch R, Marikovsky M, Meir G, Neeman M. Stimulation of tumour growth by wound-derived growth factors. Br J Cancer 1999;79:l392-8.
39. Arkonac BM, Foster LC, Sibinga NE, et al. Vascular endothelial growth factor induces heparin-binding epidermal growth factor-like growth factor in vascular endothelial cells. J Biol Chem 1998;273:4400-5.
40. Skobe M, Hawighorst T, Jackso DG, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001;7:192-8.
41. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
42. Elenius K, Paul S, Allison G, Sun J, Klagsbrun M. Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation. EMBO J 1997;16:1268-78.
43. Clark RA. Biology of dermal wound repair. Dermatol Clin 1993;11:647-66.
44. Marikovsky M, Breuing K, Liu PY, et al. Appearance of heparin-binding EGF-like growth factor in wound fluid as a response to injury. Proc Natl Acad Sci USA 1993;90:3889-93.
45. Tokumaru S, Higashiyama S, Endo T, et al. Ectodomain shedding of epidermal growth factor receptor ligands is required for keratinocyte migration in cutaneous wound healing. J Cell Biol 2000;151:209-20.
46. Iwamoto R, Handa K, Mekada E. Contact-dependent growth inhibition and apoptosis of epidermal growth factor (EOF) receptor-expressing cells by the membrane-anchored form of heparin-binding EGF-like growth factor. J Biol Chem 1999;274:25906-12.
47. Gangarosa LM, Sizemore N, Graves-Deal R, Oldham SM, Der CJ, Coffey RJ. A raf-independent epidermal growth factor receptor autocrine loop is necessary for Ras transformation of rat intestinal epithelial cells. J Biol Chem 1997;272:18926-31.
48. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature (Lond.) 1992;359:845-8.
49. Wells A. EGF receptor. Int J Biochem. Cell Biol 1999;31:637-43.
50. Hiratsuka S, Nakamura K, Iwai S, et al. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2002;2:289-300.